Clinical trial
OD vs. TID Dosing With Mesalazine Granules in Active Ulcerative Colitis
NCT00449722 · Dr. Falk Pharma GmbH, Industry · Completed
Key facts
| NCT number | NCT00449722 |
|---|---|
| Title | OD vs. TID Dosing With Mesalazine Granules in Active Ulcerative Colitis |
| Official title | Double-blind, Double-dummy, Randomised, Multicentre, Comparative Study of the Efficacy and Tolerability of Once Daily 3.0 g Mesalazine Granules Versus Three Times Daily 1.0 g Mesalazine Granules in Patients With Active Ulcerative Colitis |
| Lead sponsor | Dr. Falk Pharma GmbH, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Ulcerative Colitis |
| Intervention type | Drug |
| Interventions | mesalazine |
| Enrollment | 380 |
| Start date | Jul 1, 2005 |
| Completion | Jun 1, 2006 |
| First posted | Mar 21, 2007 |
| Last update posted | Jan 21, 2016 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: